ArticleHemaSphere2026
3D ex vivo platform for high-throughput immunotherapy screening in relapsed/refractory lymphoma patients.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsed/refractory (R/R) B-cell lymphomas (B-NHL) remain incurable, with limited predictive biomarkers to guide immunotherapy. Preclinical platforms that faithfully preserve the immune context and the viability of patient samples are critically needed for relevant high-throughput drug testing. Here, we present a 3D ex vivo platform for immunotherapy screening that generates patient-derived lymphoma spheroids (PDLS) a scaffold- and matrix-free 3D model derived from peripheral blood or lymph node biopsies of patients, including R/R follicular lymphoma, transformed follicular lymphoma, or diffuse large B-cell lymphoma. PDLS maintain the cellular composition, T-cell activation, and immune escape profiles of the original tumors, supporting multiplexed screening of single-agent and combination therapies within clinically relevant time frames. This scalable model recapitulates immune-tumor cell interactions, provides rapid assessment of immunotherapy efficacy, and bridges preclinical research with clinical application in aggressive B-cell lymphomas. By integrating spatial profiling and single-cell RNA sequencing, PDLS can further evolve into patient-specific 3D tumor avatars that support precision oncology approaches in aggressive B-NHL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.